PI-RADS Prostate MRI
On this page
Direct answer
PI-RADS v2.1 grades suspicion for clinically significant prostate cancer from 1 to 5 using multiparametric MRI — T2-weighted imaging, diffusion-weighted imaging with high b-values and apparent diffusion coefficient maps, and dynamic contrast enhancement. The decisive sequence depends on the zone: peripheral zone lesions are scored mainly on diffusion (a PI-RADS 3 lesion upgrades to 4 with positive contrast enhancement), while transition zone lesions are scored mainly on T2 appearance. Lesions scored PI-RADS 4 or 5 warrant MRI-targeted biopsy, PI-RADS 1 and 2 can be left alone, and 3 is shared decision territory. The structured score exists to standardise reporting so that "probably significant cancer" means the same thing in every centre.
What you must remember
- Zonal logic: peripheral zone — DWI is dominant, T2 is supportive; transition zone — T2 is dominant, DWI supportive. This asymmetry is the heart of v2.1.
- DWI anchor points: PI-RADS 4 is a focal lesion markedly hypointense on ADC and markedly hyperintense on high-b-value images under 1.5 cm; PI-RADS 5 adds size of at least 1.5 cm or definite extraprostatic extension.
- DCE upgrade rule: only a peripheral zone lesion scored 3 can be upgraded to 4 by positive dynamic contrast enhancement (focal early enhancement at the site of the DWI abnormality); DCE does nothing to other scores or zones.
- Transition zone T2 anchors: heterogeneous "organised chaos" is 3; lenticular or ill-defined moderately hypointense focus is 4; the same with capsule contact, bulging or spiculation is 5 — encapsulated BCH nodules are 2.
- b-value: diffusion must include a high b-value of at least 1400 s/mm², either acquired or computed, for peripheral zone scoring.
- Measurement minimum: only lesions 5 mm or larger are scored, and index lesion size drives follow-up.
- Action thresholds: PI-RADS 4-5 proceed to MRI-TRUS fusion or in-bore targeted biopsy; systematic cores are still taken in most protocols, and PI-RADS 3 with high clinical suspicion is biopsied case by case.
Scoring a gland through both zones
Take a 68-year-old with a PSA of 18 and a free-to-total ratio under 10 per cent. His study shows a 2 cm lesion in the right posterolateral peripheral zone, markedly dark on ADC, vividly bright on the computed b-2000 images, with early focal enhancement and subtle bulging of the capsule. Diffusion gives 4 on size criteria — over 1.5 cm with EPE suspicion makes it 5 outright; the T2 shows homogeneous right peripheral zone around it. Final: PI-RADS 5, index lesion in the right PZ, and the report flags the capsular bulging because that single word changes surgical planning from nerve-sparing to wide excision on that side.
In the same gland, the transition zone shows a well-marginated encapsulated nodule, uniformly bright on T2 with a dark rim — classic benign prostatic hyperplasia, PI-RADS 2 — while elsewhere in the TZ a 9 mm ill-defined lenticular moderately hypointense focus with restricted diffusion scores 4 on T2 criteria. Two lesions, two dominant sequences, one report. The examiner's favourite figure is exactly this: a DWI-bright PZ lesion to be scored on diffusion and a TZ lesion to be scored on T2, testing whether the candidate knows which ladder to climb.
Where students slip
The commonest error is applying the DCE upgrade everywhere. Positive enhancement lifts only peripheral zone 3 to 4; a transition zone 3 stays 3 no matter how dramatic the enhancement, and no lesion of any score jumps two categories. The second slip is calling every bright spot on high-b-value images a 4: T2 shine-through is excluded by checking the ADC map, and b-value imaging alone flatters. Third, candidates forget that PI-RADS scores suspicion, not diagnosis — a 5 is not a cancer verdict but a probability statement that justifies biopsy, and roughly a tenth of PI-RADS 5 lesions still prove benign. Indian practice framing: mpMRI is available mainly in large centres, so the national default pathway for an abnormal PSA remains systematic TRUS-guided biopsy, with mpMRI reserved for negative-biopsy-rising-PSA, active surveillance and staging of high-risk disease — the exam expects that tiered reality, not a utopian MRI-first algorithm.
Frequently asked questions
Which sequence dominates scoring in the peripheral versus transition zone?
Diffusion-weighted imaging dominates peripheral zone scoring, while T2-weighted morphology dominates transition zone scoring; the supporting sequence fine-tunes but rarely overrules.
When does dynamic contrast enhancement change a PI-RADS score?
Only a peripheral zone lesion scored PI-RADS 3 upgrades to 4 with positive focal early enhancement; DCE never upgrades transition zone lesions or any other score.
What defines a PI-RADS 5 lesion on diffusion imaging?
A focal markedly hypointense ADC and markedly hyperintense high-b-value abnormality measuring at least 1.5 cm, or any such lesion with definite extraprostatic extension.
Which PI-RADS categories proceed to targeted biopsy?
PI-RADS 4 and 5 lesions are biopsied under MRI-TRUS fusion or in-bore guidance, PI-RADS 3 is individualised to PSA kinetics and patient preference, and 1-2 are followed.
What high b-value is required for adequate prostate diffusion imaging?
A high b-value of at least 1400 s/mm², acquired directly or computed from lower b-values, is required for peripheral zone assessment under PI-RADS v2.1.